Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2023-12-01 DOI:10.4103/1995-7645.391781

T. B. S. Pavan, E. A. Almeida, Rodrigo Gonçalves de Lima, J. Wanderley, L. Martins, Sandra Cecília Botelho Costa, G. Marcon

{"title":"Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole","authors":"T. B. S. Pavan, E. A. Almeida, Rodrigo Gonçalves de Lima, J. Wanderley, L. Martins, Sandra Cecília Botelho Costa, G. Marcon","doi":"10.4103/1995-7645.391781","DOIUrl":null,"url":null,"abstract":"To evaluate parasitemia by qPCR in patients undergoing etiological treatment and followed in a Brazilian reference center. Parasite load was quantified by qPCR in 32 participants with chronic Chagas disease who were treated with benznidazole. Serological analyses were performed before and after the treatment and parasite loads were compared prior and 12/18 months post the treatment. Thirty-two participants were recruited and treated with benznidazole, and 20 were followed-up. Adverse events (AE) were observed in 22 out of 29 participants that had safety data (76%), and dermatological alterations were the most frequently observed AE. Of the 20 participants analyzed, 13 and 7 completed 12 and 18 months follow-up after the treatment, respectively. 12 Months after the final treatment, Trypanosoma cruzi was detectable in 3 patients by qPCR; 18 months after the final treatment, Trypanosoma cruzi was detectable per qPCR in 4 of the 7 participants. Thus, between 12 and 18 months, 7 participants of the 20 initial follow-up cases showed positive qPCR, indicating treatment failures. qPCR can be used as an alternative method for evaluating the effectiveness of the etiological treatment of CD, and can be applied to analyze early therapeutic failures. The study showed that benznidazole therapy had limited effectiveness in treating chronic CD patients, thus emphasizing the importance of conducting continued research for developing more effective therapies and diagnosis for CD.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/1995-7645.391781","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

To evaluate parasitemia by qPCR in patients undergoing etiological treatment and followed in a Brazilian reference center. Parasite load was quantified by qPCR in 32 participants with chronic Chagas disease who were treated with benznidazole. Serological analyses were performed before and after the treatment and parasite loads were compared prior and 12/18 months post the treatment. Thirty-two participants were recruited and treated with benznidazole, and 20 were followed-up. Adverse events (AE) were observed in 22 out of 29 participants that had safety data (76%), and dermatological alterations were the most frequently observed AE. Of the 20 participants analyzed, 13 and 7 completed 12 and 18 months follow-up after the treatment, respectively. 12 Months after the final treatment, Trypanosoma cruzi was detectable in 3 patients by qPCR; 18 months after the final treatment, Trypanosoma cruzi was detectable per qPCR in 4 of the 7 participants. Thus, between 12 and 18 months, 7 participants of the 20 initial follow-up cases showed positive qPCR, indicating treatment failures. qPCR can be used as an alternative method for evaluating the effectiveness of the etiological treatment of CD, and can be applied to analyze early therapeutic failures. The study showed that benznidazole therapy had limited effectiveness in treating chronic CD patients, thus emphasizing the importance of conducting continued research for developing more effective therapies and diagnosis for CD.

查看原文本刊更多论文

通过 qPCR 评估接受苯并咪唑治疗的慢性南美锥虫病患者的寄生虫血症

通过 qPCR 对接受病原学治疗并在巴西参考中心接受随访的患者的寄生虫血症进行评估。通过 qPCR 对 32 名接受苯并咪唑治疗的慢性南美锥虫病患者的寄生虫量进行量化。在治疗前后进行了血清学分析，并比较了治疗前和治疗后 12/18 个月的寄生虫数量。该研究招募了 32 名参与者，并对他们进行了苯并咪唑治疗，其中 20 人接受了随访。在有安全性数据的 29 名参与者中，有 22 人（76%）出现了不良反应（AE），皮肤病改变是最常见的不良反应。在分析的 20 名参与者中，分别有 13 人和 7 人完成了治疗后 12 个月和 18 个月的随访。最终治疗 12 个月后，3 名患者通过 qPCR 检测到了克鲁斯潘诺虫；最终治疗 18 个月后，7 名参与者中有 4 人通过 qPCR 检测到了克鲁斯潘诺虫。因此，在 12 至 18 个月期间，20 例初次随访病例中有 7 例出现了 qPCR 阳性，表明治疗失败。qPCR 可作为评价 CD 病因治疗效果的替代方法，并可用于分析早期治疗失败。该研究表明，苯并咪唑疗法对慢性 CD 患者的治疗效果有限，因此强调了继续研究开发更有效的 CD 治疗和诊断方法的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.